Needham analyst Bernie McTernan reiterates Super Group (SGHC) (NYSE:SGHC) with a Buy and maintains $5 price target.
Invitae Announces Partnership For Real-World Data Sharing To Inform Rare Cancer Research
– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research –
–